Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intuitive Wants To Vaporize Antitrust Suit: No Relevant Aftermarket Distinct From Da Vinci

Executive Summary

A group of health care providers’ class action against Intuitive Surgical alleges that the firm’s sales agreements are anticompetitive, requiring costly repairs and instrument replacements that might otherwise be purchased from independent companies. According to Intuitive, plaintiffs must demonstrate sufficient demand for da Vinci parts and services separate from da Vinci systems.

You may also be interested in...



Market Intel: Robotic Surgery Holds Great Promise, But Is Not Quite There Yet

In this final part of a three-part series on the “Future of Surgery” we highlight perspectives of a highly skilled orthopedic robotic surgeon on where we are today in robotic surgery and where we are going, introduce innovative surgical robotics companies, and discuss medtechs’ rising role in robotic surgery.

Intuitive Fights Da Vinci Surgical Robot Monopoly Claims

Intuitive Surgical is facing multiple antitrust suits that say the company took advantage of its dominant market position by demanding hospitals come to it for expensive repairs and replacements.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel